ITN0268
ITN0268
- Catalog: ITN0268
- Gene/Protein: KAT6A MOZ MYST3 RUNXBP2 ZNF220
- Product Description: Immunotag™ KAT6A Polyclonal Antibody
385.0000
Price in reward points: 385
| Antibody Specification | |
| Datasheet | 
|
| Target Protein | KAT6A |
| Clonality | Polyclonal |
| Storage/Stability | -20°C/1 year |
| Application | WB,ELISA |
| Recommended Dilution | WB 1:500-2000 ELISA 1:5000-20000 |
| Concentration | 1 mg/ml |
| Reactive Species | Human,Mouse,Rat |
| Host Species | Rabbit |
| Immunogen | Synthesized peptide derived from human protein, at AA range: 160-240 |
| Specificity | KAT6A Polyclonal Antibody detects endogenous levels of protein. |
| Purification | The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen |
| Form | Liquid in PBS containing 50% glycerol, and 0.02% sodium azide. |
| Gene Name | KAT6A MOZ MYST3 RUNXBP2 ZNF220 |
| Accession No. | Q92794 Q8BZ21 Q5TKR9 |
| Description | lysine acetyltransferase 6A(KAT6A) Homo sapiens This gene encodes a member of the MOZ, YBFR2, SAS2, TIP60 family of histone acetyltransferases. The protein is composed of a nuclear localization domain, a double C2H2 zinc finger domain that binds to acetylated histone tails, a histone acetyl-transferase domain, a glutamate/aspartate-rich region, and a serine- and methionine-rich transactivation domain. It is part of a complex that acetylates lysine-9 residues in histone 3, and in addition, it acts as a co-activator for several transcription factors. Allelic variants of this gene are associated with autosomal dominant mental retardation-32. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Apr 2015], |
| Protein Expression | Bone marrow,Donated clones,Epithelium, |
| Subcellular Localization | nucleosome,nucleus,nucleoplasm,nucleolus,Golgi apparatus,PML body,MOZ/MORF histone acetyltransferase complex, |
| Protein Function | catalytic activity:Acetyl-CoA + histone = CoA + acetylhistone.,disease:A chromosomal aberration involving MYST3 is a cause of therapy-related myelodysplastic syndrome. Translocation t(2;8)(p23;p11.2) with ASXL2 generates a MYST3-ASXL2 fusion protein.,disease:Chromosomal aberrations involving MYST3 may be a cause of acute myeloid leukemias. Translocation t(8;16)(p11;p13) with CREBBP; translocation t(8;22)(p11;q13) with EP300. MYST3-CREBBP may induce leukemia by inhibiting RUNX1-mediated transcription. Inversion inv(8)(p11;q13) generates the MYST3-NCOA2 oncogene, which consists of the N-terminus part of MYST3/MOZ and the C-terminus part of NCOA2/TIF2. MYST3-NCOA2 binds to CREBBP and disrupts its function in transcription activation.,domain:The N-terminus is involved in transcriptional activation while the C-terminus is involved in transcriptional repression.,function:Component of the MOZ/MORF complex which has a histone H3 acetyltransferase activity. Histone acetyltransferase which may act as a transcriptional coactivator for RUNX1 and RUNX2.,PTM:Autoacetylated.,PTM:Phosphorylated upon DNA damage, probably by ATM or ATR.,similarity:Belongs to the MYST (SAS/MOZ) family.,similarity:Contains 1 C2HC-type zinc finger.,similarity:Contains 2 PHD-type zinc fingers.,subcellular location:Partially concentrated in subnuclear foci distinct from PML bodies, and excluded from the nucleoli.,subunit:Component of the MOZ/MORF composed at least of ING5, MYST3/MOZ, MYST4/MORF and one of BRPF1, BRD1/BRPF2 and BRPF3. Interacts with RUNX1; phosphorylation of RUNX1 enhances the interaction. Interacts with RUNX2., |
| Usage | For Research Use Only! Not for diagnostic or therapeutic procedures. |
| Material Safety Data Sheet | |
| English_US |
|
| Danish |
|
| Dutch |
|
| English_UK |
|
| French |
|
| German |
|
| Spanish |
|
| Norwegian |
|
| Portuguese |
|
| Finnish |
|
| Swedish |
|
| Polish |
|